Podrobno

Optimizing patient access to orphan medicinal products: lessons from Central and Eastern Europe
ID Kluszczynski, Tomasz (Avtor), ID Németh, Bertalan (Avtor), ID Władysiuk, Magdalena (Avtor), ID Czech, Marcin (Avtor), ID Kamusheva, Maria (Avtor), ID Fotin, Nicolae (Avtor), ID Rose, Sandra (Avtor), ID Doležal, Tomáš (Avtor), ID Hren, Rok (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (2,08 MB)
MD5: 7ED97C97E4FD5FAAF136B7F9292B33E0
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2001-6689/13/2/24 Povezava se odpre v novem oknu

Izvleček
This study examines patient access to orphan medicinal products (OMPs) in Central and Eastern Europe (CEE) over the past five years, focusing on seven countries: Bulgaria, Czechia, Hungary, Poland, Romania, Slovakia, and Slovenia. While these jurisdictions have undergone rapid healthcare transformations, significant disparities in OMP access persist compared to Western Europe. This study aimed to address this gap by identifying barriers and enablers to optimize patient access to OMPs in a sustainable and equitable manner. A mixed-methodology approach was utilized, combining systematic literature reviews, in-depth interviews, and advisory board insights. Perspectives were gathered from a wide range of stakeholders, including policymakers, payers, academia, industry associations, and patient advocacy groups. Additionally, the study incorporated data from CEE-specific initiatives to triangulate findings and evaluate barriers, enablers, and best practices in OMP access. The analysis identified sub-optimal OMP access across most CEE countries, marked by prolonged delays and lower reimbursement rates compared to Western Europe, with Slovenia and Czechia as notable exceptions. Key barriers include limited awareness, inadequate health technology assessment (HTA) frameworks, insufficient financing mechanisms, underutilization of novel access schemes, and fragmented patient engagement. Conversely, enablers include the presence of rare disease policies, OMP-specific HTA frameworks, and patient-inclusive decision-making processes.

Jezik:Angleški jezik
Ključne besede:healthcare, rare diseases, orphan medicinal products, patient access
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FMF - Fakulteta za matematiko in fiziko
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:15 str.
Številčenje:Vol. 13, iss. 2, art. no. 24
PID:20.500.12556/RUL-169435 Povezava se odpre v novem oknu
UDK:614:615
ISSN pri članku:2001-6689
DOI:10.3390/jmahp13020024 Povezava se odpre v novem oknu
COBISS.SI-ID:237516291 Povezava se odpre v novem oknu
Datum objave v RUL:28.05.2025
Število ogledov:311
Število prenosov:51
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of market access & health policy
Skrajšan naslov:J. mark. access health policy
Založnik:Co-Action Publishing, Co-Action Publishing, Taylor & Francis Group, MDPI
ISSN:2001-6689
COBISS.SI-ID:524322841 Povezava se odpre v novem oknu

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:zdravstvo, redke bolezni, zdravila sirote, dostopnost

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj